Charles Milstein - Vertex Pharmaceuticals President

VRTX -- USA Stock  

USD 176.14  1.62  0.93%

Mr. Michael J. Parini, J.D. is Executive Vice President, Chief Legal and Administrative Officer of the Vertex Pharmaceuticals Incorporated. Mr. Parini is our Executive Vice President and Chief Legal and Administrative Officer, a position he has held since January 2017. From January 2016 to January 2017, he was our Executive Vice President and Chief Legal Officer. From 2004 until he joined Vertex, Mr. Parini served in various roles of increasing responsibility at Pfizer Inc., a pharmaceutical company, most recently as Senior Vice President and Associate General Counsel. Prior to Pfizer, Mr. Parini was an attorney at Akin, Gump, Strauss, Hauer Feld, L.L.P
Age: 42  President Since 2017      
Parini holds a B.A. from Georgetown University and a J.D. from the Georgetown University Law Center.

Management Efficiency

The company has return on total asset (ROA) of 9.99 % which means that it generated profit of $9.99 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 56.25 % meaning that it created $56.25 on every $100 dollars invested by stockholders.
The company currently holds 656.95M in liabilities with Debt to Equity (D/E) ratio of 12.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vertex Pharmaceuticals has Current Ratio of 3.67 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives


Michael AbermanRegeneron Pharmaceuticals
Kristin PeckZoetis
Michael StewartPerrigo Company plc
Andrew FentonZoetis
Samiran DasDr Reddys Laboratories Ltd
Christopher FenimoreRegeneron Pharmaceuticals
K RaoDr Reddys Laboratories Ltd
Ganadhish KamatDr Reddys Laboratories Ltd
Douglas McCorkleRegeneron Pharmaceuticals
Stefan WeiskopfZoetis
Sripada ChandrasekharDr Reddys Laboratories Ltd
Peter PowchikRegeneron Pharmaceuticals
Saumen ChakrabortyDr Reddys Laboratories Ltd
Roman TrawickiZoetis
Umang VohraDr Reddys Laboratories Ltd
James MichaudPerrigo Company plc
Alok SonigDr Reddys Laboratories Ltd
John HendricksonPerrigo Company plc
Jatin ShahPerrigo Company plc
Sandra BeatyZoetis
Grainne QuinnPerrigo Company plc

Entity Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 2500 people.Vertex Pharmaceuticals Incorpor (VRTX) is traded on BATS Exchange in USA and employs 2,500 people.

Vertex Pharmaceuticals Leadership Team

William Young, Independent Director
Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Michael Parini, Executive Vice President and Chief Legal Officer
Alan Garber, Independent Director
Joshua Boger, Executive Director and Chairman of Science and Technology Committee
John Gray, Senior Vice President Genetic Therapies
Margaret McGlynn, Independent Director
Sangeeta Bhatia, Director
Terrence Kearney, Independent Director
Ian Smith, CFO, Executive Vice President
Paul Silva, Senior Vice President Corporate Controller
David Altshuler, Independent Director
Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines Development
Elaine Ullian, Co-Lead Independent Director
Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and Value
David Greenway, Director
Charles Wagner, CFO, Executive Vice President
Bruce Sachs, Co-Lead Independent Director
Lloyd Carney, Independent Director
Michael Partridge, Vice President - Investor Relations
Yuchun Lee, Independent Director
Kimberly White, Senior Vice President and Chief Communications Officer
Stuart Arbuckle, Chief Commercial Officer and Executive VP
Thomas Graney, CFO, Senior Vice President
Charles Milstein, Executive Vice President Chief Legal and Administrative Officer
Jeffrey Leiden, Chairman of the Board and Presidentident, CEO

Stock Performance Indicators

Current Sentiment - VRTX

Vertex Pharmaceuticals Investor Sentiment

Most of Macroaxis users are at this time bullish on Vertex Pharmaceuticals Incorpor. What is your outlook on investing in Vertex Pharmaceuticals Incorpor? Are you bullish or bearish?
98% Bullish
2% Bearish

Also Currentnly Active

Purchased few shares of
few hours ago
Traded for 188.14
Purchased a lot of shares of
few hours ago
Traded for 150.35
Purchased few shares of
few hours ago
Traded for 175.29
Also please take a look at World Market Map. Please also try Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.